This analysis examines the historical and forecast performance for Sanofi-Aventis in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Sanofi-Aventis's performance against key rivals in the ethical pharmaceutical sector See how, as 2012 approaches, the company's mature core product portfolio will face an increased risk of generic exposure, hampering sales growth Evaluate the prospects of the Sanofi-Aventis's late-stage pipeline, which must fulfill its potential if growth is to be sustained in the long term.